Solutions pour la dcouverte du mdicament orphelin Brigitte
Solutions pour la découverte du médicament orphelin Brigitte Onteniente, Présidente Julien Maruotti, Directeur scientifique PHENOCELL SAS - 4, rue Pierre Fontaine - 91058 Evry cedex - FRANCE
Our mission and aim Accelerate Orphan Drug Discovery predictive with relevant and predictive cellular models and associated phenotypic assays 2
Why Phenocell ? 3
Products and services 4
The i. PSC technology Somatic cells Reprogramming factors i. PS cells Mesoderm Heart Skeletal muscle Kidney Blood Endoderm Smooth muscle Lung Pancreas Thyroid Ectoderm Epiderm Neural cells Retina 5
Why Phenotypic Screening ? Retinal pigment epithelium Adipocytes Neural stem cells Osteoblasts Mesenchymal stem cells Melanocytes Keratinocytes Pluristratified epidermis 6
Optimized models and Pheno. Tests for: Hits validation Lead validation Expérimental Research Pathological modelling In vitro ADME-TOX 7 7
Why PHENOCELL ? 8
Facts and Numbers o From inception: september 2013 4 contracts (industry and academia) 4 new jobs 5 students (L 3 Pro, M 2, Sup. Biotech) 1 Ph. D student (CIFRE contract) Individualisation from I-Stem to the GENOPOLE®/CCI incubator 2013: 2014: HEC Challenge+ recognition and courses (BO) Winner of the “Emergence” prize of the MESR-Bpifrance Prêt d’Honneur Scientipôle Initiative (BO) Winner of the “i. LAB” prize of the MESR-Bpifrance Objectif One financial help (Scientipôle Croissance) o Future development Investment funding for : - development of robotised production of cellular models - Starting drug development programs with phenotypic assays
Your Contacts Brigitte Onteniente, CEO Julien Maruotti, CSO contact@phenocell. com Tel: +33 (0)1 6087 8988 Fax: +33 (0)1 6087 8990 www. phenocell. com PHENOCELL SAS GENOPOLE® Entreprises 4, rue Pierre Fontaine 91058 Evry cedex FRANCE 10
- Slides: 10